Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

J.P. Wijnen; L. Jiang; T.R. Greenwood; M. Cheng; M. Döpkens; M.D. Cao; Z.M. Bhujwalla; B. Krishnamachary; D.W.J. Klomp; K. Glunde

doi:10.1002/nbm.3106

Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

J.P. Wijnen, L. Jiang, T.R. Greenwood, M. Cheng, M. Döpkens, M.D. Cao, Z.M. Bhujwalla, B. Krishnamachary, D.W.J. Klomp, K. Glunde^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (P-31) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors. Copyright (c) 2014 John Wiley & Sons, Ltd.

Original language	English
Pages (from-to)	692-699
Number of pages	8
Journal	NMR in Biomedicine
Volume	27
Issue number	6
DOIs	https://doi.org/10.1002/nbm.3106
Publication status	Published - 2014

Keywords

P-31 MRS
metabolism
in vivo
breast cancer
glycerophosphoesterdiesterase
GDPD5
silencing
MAGNETIC-RESONANCE-SPECTROSCOPY
P-31 NMR-SPECTROSCOPY
MALIGNANT-TRANSFORMATION
MAMMALIAN-CELLS
TUMOR-CELLS
CHOLINE
EXPRESSION
INHIBITION
PHOSPHATIDYLETHANOLAMINE
QUANTIFICATION

Access to Document

10.1002/nbm.3106

http://www.ncbi.nlm.nih.gov/pubmed/24764256

Cite this

Wijnen, J. P., Jiang, L., Greenwood, T. R., Cheng, M., Döpkens, M., Cao, M. D., Bhujwalla, Z. M., Krishnamachary, B., Klomp, D. W. J., & Glunde, K. (2014). Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS. NMR in Biomedicine, 27(6), 692-699. https://doi.org/10.1002/nbm.3106

@article{ad3d1b58b51c41328769941e4d800d92,

title = "Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS",

abstract = "Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (P-31) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors. Copyright (c) 2014 John Wiley & Sons, Ltd.",

keywords = "P-31 MRS, metabolism, in vivo, breast cancer, glycerophosphoesterdiesterase, GDPD5, silencing, MAGNETIC-RESONANCE-SPECTROSCOPY, P-31 NMR-SPECTROSCOPY, MALIGNANT-TRANSFORMATION, MAMMALIAN-CELLS, TUMOR-CELLS, CHOLINE, EXPRESSION, INHIBITION, PHOSPHATIDYLETHANOLAMINE, QUANTIFICATION",

author = "J.P. Wijnen and L. Jiang and T.R. Greenwood and M. Cheng and M. D{\"o}pkens and M.D. Cao and Z.M. Bhujwalla and B. Krishnamachary and D.W.J. Klomp and K. Glunde",

year = "2014",

doi = "10.1002/nbm.3106",

language = "English",

volume = "27",

pages = "692--699",

journal = "NMR in Biomedicine",

issn = "0952-3480",

publisher = "John Wiley & Sons Inc.",

number = "6",

}

Wijnen, JP, Jiang, L, Greenwood, TR, Cheng, M, Döpkens, M, Cao, MD, Bhujwalla, ZM, Krishnamachary, B, Klomp, DWJ & Glunde, K 2014, 'Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS', NMR in Biomedicine, vol. 27, no. 6, pp. 692-699. https://doi.org/10.1002/nbm.3106

TY - JOUR

T1 - Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

AU - Wijnen, J.P.

AU - Jiang, L.

AU - Greenwood, T.R.

AU - Cheng, M.

AU - Döpkens, M.

AU - Cao, M.D.

AU - Bhujwalla, Z.M.

AU - Krishnamachary, B.

AU - Klomp, D.W.J.

AU - Glunde, K.

PY - 2014

Y1 - 2014

N2 - Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (P-31) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors. Copyright (c) 2014 John Wiley & Sons, Ltd.

AB - Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (P-31) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors. Copyright (c) 2014 John Wiley & Sons, Ltd.

KW - P-31 MRS

KW - metabolism

KW - in vivo

KW - breast cancer

KW - glycerophosphoesterdiesterase

KW - GDPD5

KW - silencing

KW - MAGNETIC-RESONANCE-SPECTROSCOPY

KW - P-31 NMR-SPECTROSCOPY

KW - MALIGNANT-TRANSFORMATION

KW - MAMMALIAN-CELLS

KW - TUMOR-CELLS

KW - CHOLINE

KW - EXPRESSION

KW - INHIBITION

KW - PHOSPHATIDYLETHANOLAMINE

KW - QUANTIFICATION

U2 - 10.1002/nbm.3106

DO - 10.1002/nbm.3106

M3 - Article

C2 - 24764256

SN - 0952-3480

VL - 27

SP - 692

EP - 699

JO - NMR in Biomedicine

JF - NMR in Biomedicine

IS - 6

ER -

Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

Abstract

Keywords

Access to Document

Fingerprint

Cite this